Plasma proteins in acute and chronic lung disease of the newborn.
This study compared plasma levels of albumin, transferrin, and ceruloplasmin in well preterm babies (n = 21) with those with respiratory distress syndrome (RDS, n = 13) and chronic lung disease (CLD, n = 13) over the first 28 postnatal days. Plasma lipid peroxidation, total radical trapping capacity (TRAP assay), and iron binding antioxidant capacity were also measured. In RDS and CLD albumin levels were decreased on days 1, 4 and 10; on day 10 albumin was lower in CLD compared to RDS (p < .05). After day 10 the levels were similar in all groups. The transferrin levels showed a similar trend. Ceruloplasmin levels did not differ, except for a higher day 28 level in CLD (p < .05). Albumin levels significantly decreased with increasing FiO2 and duration of oxygen therapy (within patient r = -0.30, p < .05 and r = -0.51, p < .005, respectively). On day 10, increasing oxygen therapy increased plasma lipid peroxidation (r = +0.49, p < .01), which was also significantly related to lower plasma protein levels (r = -0.42, p < .01). Lower plasma albumin and transferrin lowered the TRAP and iron binding antioxidant capacity, respectively (r = +0.36, p < .05, and r = +0.41, p < .005). Prediction of CLD using day 10 albumin levels had a specificity of 94%, but a sensitivity of only 50%. The interaction between oxygen toxicity and high ventilation pressures in immature babies appears to lower plasma proteins by increasing pulmonary permeability. The lower plasma albumin level was not useful in predicting the development of CLD; however, the fall in plasma transferrin and albumin will further decrease the preventive and chain-breaking antioxidant capacity of plasma of these ill babies.
Moison
R M
RM
Department of Pediatrics, Leiden University Hospital, The Netherlands. a.m.w.moison@kgc.azl.nl
Haasnoot
A A
AA
Van Zoeren-Grobben
D
D
Berger
H M
HM
D000975:Antioxidants; D001798:Blood Proteins / Q000378:metabolism*; D002570:Ceruloplasmin / Q000378:metabolism; D002908:Chronic Disease; D003907:Dexamethasone / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D016166:Free Radical Scavengers; D006801:Humans; D007231:Infant, Newborn; D007234:Infant, Premature / Q000097:blood*; D015227:Lipid Peroxidation; D008171:Lung Diseases / Q000097:blood* / Q000628:therapy; D008297:Male; D008315:Malondialdehyde / Q000378:metabolism; D010100:Oxygen / Q000008:administration & dosage / Q000627:therapeutic use; D012127:Respiratory Distress Syndrome, Newborn / Q000097:blood* / Q000628:therapy; D012709:Serum Albumin / Q000378:metabolism; D014168:Transferrin / Q000378:metabolism
D000975:Antioxidants; D001798:Blood Proteins; D016166:Free Radical Scavengers; D012709:Serum Albumin; D014168:Transferrin; D008315:Malondialdehyde; D003907:Dexamethasone; D002570:Ceruloplasmin; D010100:Oxygen